We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.09B
AUM Growth
+$551M
Cap. Flow
+$510M
Cap. Flow %
24.34%
Top 10 Hldgs %
59.78%
Holding
66
New
16
Increased
22
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.8M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$50.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$44.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.8M
5
DERM
Dermira, Inc.
DERM
+$41.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$56.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.8M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$9.2M
5
AGEN
Agenus
AGEN
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 83.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
CALL
Acadia Pharmaceuticals
ACAD
$4.93B
$363K 0.02%
+500,000
New +$13.8M
BMRN icon
52
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
$214K 0.01%
162,500
-137,500
-46% -$11.8M
MGNX icon
53
CALL
MacroGenics
MGNX
$248M
$72K ﹤0.01%
14,500
– –
ONSIZ
54
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$12K ﹤0.01%
233,333
– –
ONSIW
55
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$5K ﹤0.01%
233,333
– –
BCRX icon
56
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-340,821
Closed -$1.67M
BMY icon
57
Bristol-Myers Squibb
BMY
$130B
– –
-456,223
Closed -$28M
CLLS
58
Cellectis
CLLS
$281M
– –
-78,289
Closed -$2.28M
INCY icon
59
Incyte
INCY
$24.3B
– –
-50,000
Closed -$4.74M
LUMO
60
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-88,379
Closed -$6.45M
CLVS
61
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-675,000
Closed -$264K
MYOK
62
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-398,207
Closed -$16.8M
IMMU
63
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-875,000
Closed -$8.22M
ARRY
64
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-75,000
Closed -$216K
CASC
65
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-2,485,272
Closed -$9.2M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Avoro Capital Advisors held 66 positions worth $2.09B, up 36% from $1.54B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $510M of net new capital in Q1 2018, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Puma Biotechnology: 825,368 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $56.8M trimmed.

  • Avoro Capital Advisors's largest Q1 2018 buy was Puma Biotechnology: 825,368 shares worth $56.2M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q1 2018, an estimated $44.8M increase.
  • Avoro Capital Advisors's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $56.8M.
  • Avoro Capital Advisors fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $28M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $2.09B portfolio in Q1 2018.
  • Avoro Capital Advisors opened 16 new positions and closed 10 in Q1 2018.
  • Avoro Capital Advisors's portfolio value rose 36% quarter-over-quarter to $2.09B.

Based on Avoro Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.